Janux Therapeutics (NASDAQ:JANX) Posts Earnings Results, Beats Expectations By $0.13 EPS

Janux Therapeutics (NASDAQ:JANX) announced its quarterly earnings results on Thursday. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13, Zacks reports. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Janux Therapeutics Price Performance

Shares of JANX stock traded down $0.59 during trading hours on Thursday, reaching $32.01. 425,109 shares of the company traded hands, compared to its average volume of 1,026,279. The firm has a 50-day moving average price of $44.72 and a 200 day moving average price of $47.95. The company has a market cap of $1.68 billion, a P/E ratio of -27.36 and a beta of 3.16. Janux Therapeutics has a 12-month low of $31.69 and a 12-month high of $71.71.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JANX. Stifel Nicolaus raised their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. BTIG Research raised their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. HC Wainwright lifted their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Finally, Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $89.90.

Insider Buying and Selling

In related news, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the transaction, the chief executive officer now owns 242,054 shares in the company, valued at approximately $16,217,618. The trade was a 5.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,668 shares of company stock valued at $3,582,515. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.